PCSK9 and diabetes mellitus: While some studies suggest that statin therapy may modestly elevate diabetes incidence in non-diabetic individuals or worsen glycemic control in patients with type 2 diabetes (T2DM), large-scale clinical trials have consistently demonstrated that PCSK9 inhibitor treatment does not increase diabetes risk (Goodman et al., 2023; Livingstone et al., 2016).